BIOSIGN ANNOUNCES START OF GAMUT GLUCOMETRY TRIAL

							      FOR IMMEDIATE RELEASE

              BIOSIGN ANNOUNCES START OF GAMUT GLUCOMETRY TRIAL
      TORONTO, ONTARIO, January 25, 2007 – Biosign Technologies Inc. (CNQ: BIOS)
      announces today the start of its GAMUT trial. The multi-track study will further substantiate the
      measurement capabilities of Biosign’s UFIT™ system. The first track, GAMUT-1, will assess the
      substantial equivalence of UFIT™ with the laboratory analysis of venous blood glucose, which is
      the “gold standard” for blood glucose measurement in medical practice.

      GAMUT-1 will also assess the substantial equivalence of UFIT™ with a top-selling glucometer,
      which uses capillary blood obtained by lancing the skin. Such glucometers are routinely
      recommended for diabetes self-care.

      UFIT™ computes the glucose level in the arterial blood from its flow characteristics, while
      measuring blood pressure. The method shares the general characteristics of UFIT™ technology:
      noninvasive and user-friendly, readily accessible over the Internet according to local regulations,
      runtime quality assurance with prompt detection and recall of defective units, and results
      verifiable for technical accuracy and clinical relevance.

      GAMUT will observe recent regulatory guidances on medical device trials, including the use of
      ISO standards and Bayesian statistics. This allows the inclusion of Biosign’s prior studies.

      GAMUT-1 is scheduled for presentation at an international workshop on medical measurements
      and applications in April, 2007.

      About Biosign

      Biosign develops technologies, products and initiatives to address critical problems in global
      health care. The focus is on measuring health status, outcomes, and risk toward maximizing
      clinical awareness, readiness, and effectiveness. The thrust is on enabling autonomous medical
      care along the axis of quality, access, and cost. The core technology expands virtual
      instrumentation with universal measurement and rapid knowledge formation to support service
      oriented enterprising across global markets. Trademarked UFIT, the web-based technology
      powers several business lines in adaptive clinical trials, self-care, medical homes, distributed
      diagnostics and home health care. Regulated applications include intelligent systems for
      noninvasive monitoring at the point of care, useful in optimizing health and managing chronic
      diseases such as hypertension and diabetes.

      Contact:

      Richard Potts, Chairman & CEO                              Dr. Radu Leca, President & CTO
      Phone: (416) 218-9800 ext. 234                             Phone: (416) 218-9800 ext. 225
      Email: richardp@biosign.com                                Email: radul@biosign.com


Biosign Technologies Inc. 25 Sheppard Avenue West, Suite 1010, Toronto, Ontario M2N 6S6 Tel 416-218-9800 • Fax 416-218-9008